Appili Therapeutics Inc T.APLI

Alternate Symbol(s): APLIF

Healthcare

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

TSX:APLI - Post by User

Appili Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by bmreedon Apr 11, 2022 10:32am

161 Views

Post# 34593512

Webinar Recap w Radius Research & $APLI CEO Armand Balboni

Webinar Recap: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni - Drug Development Focused on Infectious Diseases - Pitch, Deep Dive, and Q&A - https://www.youtube.com/watch?v=xGrmHACzU7c